Cargando…
Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564452/ https://www.ncbi.nlm.nih.gov/pubmed/32854393 http://dx.doi.org/10.3390/cancers12092414 |
_version_ | 1783595718184796160 |
---|---|
author | Reverdy, Thibaut Sajous, Christophe Péron, Julien Glehen, Olivier Bakrin, Naoual Gertych, Witold Lopez, Jonathan You, Benoit Freyer, Gilles |
author_facet | Reverdy, Thibaut Sajous, Christophe Péron, Julien Glehen, Olivier Bakrin, Naoual Gertych, Witold Lopez, Jonathan You, Benoit Freyer, Gilles |
author_sort | Reverdy, Thibaut |
collection | PubMed |
description | Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based chemotherapy. Most patients experience a relapse in the years following the initial treatment. During the last decade, anti-angiogenic agents used in the maintenance setting improved progression free survival (PFS) over chemotherapy alone. More recently, PARP inhibitors demonstrated substantial efficacy, mainly in patients with germinal or somatic BRCA mutations or other homologous recombination deficiencies (HRD), all involved in double strand DNA Damage Repair (DDR). Other therapeutic paradigms are currently being explored, including combinations of immune-checkpoints inhibitors, chemotherapy, bevacizumab and PARP inhibitors. In addition to these clinical advances, molecular characterization of the tumors and their correlations with drugs efficacy are needed to better understand which patient will benefit the most from the various treatments available to date. |
format | Online Article Text |
id | pubmed-7564452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75644522020-10-26 Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives Reverdy, Thibaut Sajous, Christophe Péron, Julien Glehen, Olivier Bakrin, Naoual Gertych, Witold Lopez, Jonathan You, Benoit Freyer, Gilles Cancers (Basel) Review Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based chemotherapy. Most patients experience a relapse in the years following the initial treatment. During the last decade, anti-angiogenic agents used in the maintenance setting improved progression free survival (PFS) over chemotherapy alone. More recently, PARP inhibitors demonstrated substantial efficacy, mainly in patients with germinal or somatic BRCA mutations or other homologous recombination deficiencies (HRD), all involved in double strand DNA Damage Repair (DDR). Other therapeutic paradigms are currently being explored, including combinations of immune-checkpoints inhibitors, chemotherapy, bevacizumab and PARP inhibitors. In addition to these clinical advances, molecular characterization of the tumors and their correlations with drugs efficacy are needed to better understand which patient will benefit the most from the various treatments available to date. MDPI 2020-08-25 /pmc/articles/PMC7564452/ /pubmed/32854393 http://dx.doi.org/10.3390/cancers12092414 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Reverdy, Thibaut Sajous, Christophe Péron, Julien Glehen, Olivier Bakrin, Naoual Gertych, Witold Lopez, Jonathan You, Benoit Freyer, Gilles Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives |
title | Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives |
title_full | Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives |
title_fullStr | Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives |
title_full_unstemmed | Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives |
title_short | Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives |
title_sort | front-line maintenance therapy in advanced ovarian cancer—current advances and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564452/ https://www.ncbi.nlm.nih.gov/pubmed/32854393 http://dx.doi.org/10.3390/cancers12092414 |
work_keys_str_mv | AT reverdythibaut frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives AT sajouschristophe frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives AT peronjulien frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives AT glehenolivier frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives AT bakrinnaoual frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives AT gertychwitold frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives AT lopezjonathan frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives AT youbenoit frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives AT freyergilles frontlinemaintenancetherapyinadvancedovariancancercurrentadvancesandperspectives |